BioMarin Pharmaceutical (BMRN)
NASDAQ: BMRN · Biotechnology · Novato, CA
Our rating: Positive
Call changed from Neutral to Positive at $57.13, moderate conviction, November 4, 2026.
Breaks if: The call turns Cautious if reported revenue growth, as disclosed in the next two quarterly filings, decelerates to below 5% on a trailing twelve-month basis — particularly if attributed to volume or pricing pressure in a product touched by the October 2026 invalidation. It would also turn Cautious if free cash flow falls below $500M on an annualized basis in any single quarter, indicating the underlying cash economics have weakened rather than merely diverged from reported earnings on accounting timing.
Key figures
| Market value | $11.7B |
|---|---|
| Revenue, last 12 months | $3.7B |
| Net income, last 12 months | −$19M |
| Free cash flow, last 12 months | $558M |
| Price to earnings | n/a |
| Free cash flow yield | 4.8% |
| Dividend yield | 0.0% |
| Operating margin | 3.1% |
| Return on equity | −0.3% |
| Beta to the S&P 500 | 0.59 |
| Volatility, annualized | 33.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.0B | 32.0% | $-0.63 | $160M |
| June 30, 2026 | $990M | 19.9% | $0.23 | $139M |
| March 31, 2026 | $766M | 2.8% | $0.54 | $200M |
| December 31, 2025 | $875M | 17.0% | $-0.24 | $59M |
| September 30, 2025 | $776M | 4.1% | $-0.16 | $340M |
| June 30, 2025 | $825M | 15.9% | $1.23 | $168M |
| March 31, 2025 | $745M | 14.8% | $0.95 | $158M |
| December 31, 2024 | $747M | 15.6% | $0.65 | $166M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.03B: Claude 72%, Gemini 88%, Mistral 72%
- Diluted earnings per share are above zero: Claude 45%, Gemini 55%, Mistral 55%
- Free cash flow for the quarter is at least $0.06B: Claude 70%, Gemini 97%, Mistral 88%
13 ledger entries and 45 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.